A detailed history of Janus Henderson Group PLC transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Janus Henderson Group PLC holds 1,965,546 shares of JANX stock, worth $81.5 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
1,965,546
Previous 1,931,477 1.76%
Holding current value
$81.5 Million
Previous $20.7 Million 257.08%
% of portfolio
0.04%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$7.93 - $49.75 $270,167 - $1.69 Million
34,069 Added 1.76%
1,965,546 $74 Million
Q4 2023

Feb 14, 2024

SELL
$5.85 - $11.7 $795,547 - $1.59 Million
-135,991 Reduced 6.58%
1,931,477 $20.7 Million
Q3 2023

Nov 14, 2023

SELL
$9.56 - $14.0 $400,277 - $586,180
-41,870 Reduced 1.98%
2,067,468 $20.8 Million
Q2 2023

Aug 14, 2023

BUY
$11.08 - $15.92 $2.66 Million - $3.82 Million
240,262 Added 12.85%
2,109,338 $25 Million
Q1 2023

May 15, 2023

BUY
$11.25 - $22.21 $351,956 - $694,839
31,285 Added 1.7%
1,869,076 $22.6 Million
Q4 2022

Feb 14, 2023

SELL
$11.1 - $18.26 $1.36 Million - $2.23 Million
-122,253 Reduced 6.24%
1,837,791 $24.2 Million
Q3 2022

Nov 14, 2022

SELL
$10.82 - $16.84 $1.82 Million - $2.82 Million
-167,753 Reduced 7.88%
1,960,044 $26.5 Million
Q2 2022

Aug 15, 2022

SELL
$9.52 - $15.65 $2.01 Million - $3.31 Million
-211,349 Reduced 9.04%
2,127,797 $26 Million
Q1 2022

May 16, 2022

SELL
$13.24 - $20.24 $817,530 - $1.25 Million
-61,747 Reduced 2.57%
2,339,146 $33.5 Million
Q4 2021

Feb 14, 2022

SELL
$15.44 - $27.32 $239,489 - $423,760
-15,511 Reduced 0.64%
2,400,893 $46.6 Million
Q3 2021

Nov 16, 2021

SELL
$20.7 - $34.69 $5.21 Million - $8.74 Million
-251,803 Reduced 9.44%
2,416,404 $51.4 Million
Q2 2021

Aug 16, 2021

BUY
$18.58 - $25.37 $49.6 Million - $67.7 Million
2,668,207 New
2,668,207 $64.5 Million

Others Institutions Holding JANX

About Janux Therapeutics, Inc.


  • Ticker JANX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,663,000
  • Market Cap $1.73B
  • Description
  • Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...
More about JANX
Track This Portfolio

Track Janus Henderson Group PLC Portfolio

Follow Janus Henderson Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.